Phil Brandish
Chief Scientific Officer AI Proteins
Seminars
Thursday 30th April 2026
Discovery & Characterization of a Selective, Pure Antagonist of TNFR1
11:30 am
- Introducing de novo designed miniproteins as a next generation therapeutic modality
- Highlighting the application to antagonism of TNFR1
- Showcasing differentiation against existing therapies
